Journal article
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab
Abstract
BACKGROUND & AIMS: We have previously validated a clinical decision support tool (CDST) (vedolizumab CDST [VDZ-CDST]) for clinical and endoscopic remission with VDZ in ulcerative colitis (UC). We aim to expand the validation for predicting histoendoscopic mucosal improvement (HEMI) with VDZ vs adalimumab (ADA).
METHODS: In a post hoc analysis of a clinical trial for VDZ vs ADA in moderate to severe UC (VARSITY trial; NCT02497469), comparative …
Authors
Dulai PS; Wong ECL; Reinisch W; Colombel J-F; Marshall JK; Narula N
Journal
Inflammatory Bowel Diseases, Vol. 28, No. 10, pp. 1555–1564
Publisher
Oxford University Press (OUP)
Publication Date
October 3, 2022
DOI
10.1093/ibd/izab310
ISSN
1078-0998